(BCAT) BlackRock Capital - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09260U1097

Stock: Equities, Debt Securities, Leverage, Convertibles, Options

Total Rating 49
Risk 77
Buy Signal 1.06
Asset Management » Asset Management & Custody Banks
Age: 5.4y
Market Cap: 1,540m
Avg Trading Vol: 10.5M USD
ATR: 1.09%
Peers RS (IBD): 72.22

EPS (Earnings per Share)

EPS (Earnings per Share) of BCAT over the last years for every Quarter: "2020-12": null, "2021-06": 1.39, "2021-12": -0.31, "2022-06": -3.06, "2022-12": 0.15, "2023-12": null, "2024-12": null,
EPS CAGR: -94.86%
EPS Trend: -46.8%
Qual. Beats: 0

Revenue

Revenue of BCAT over the last years for every Quarter: 2020-12: null, 2021-06: null, 2021-12: null, 2022-06: null, 2022-12: null, 2023-12: null, 2024-12: null,
Rev. CAGR: 0.00%
Qual. Beats: 0

Dividends

Dividend Yield 22.44%
Yield on Cost 5y 31.23%
Yield CAGR 5y 27.71%
Payout Consistency 92.1%
Payout Ratio 226.7%
Risk 5d forecast
Volatility 12.1%
Relative Tail Risk 0.93%
Reward TTM
Sharpe Ratio 1.01
Alpha 8.47
Character TTM
Beta 0.534
Beta Downside 0.535
Drawdowns 3y
Max DD 13.69%
CAGR/Max DD 1.27

Description: BCAT BlackRock Capital January 16, 2026

BlackRock Capital Allocation Trust (NYSE: BCAT) is a U.S.-based common stock that operates within the Asset Management & Custody Banks sub-industry of the GICS classification. The fund’s mandate is to allocate capital across a diversified set of BlackRock-managed strategies, aiming to deliver long-term total return while maintaining a flexible, opportunistic investment approach.

Key metrics as of the latest filing show assets under management of roughly $1.2 billion, an expense ratio of 0.85 %, and a trailing-12-month dividend yield near 2.1 %. The trust’s performance is closely tied to macro-level drivers such as interest-rate trends (which influence fee structures for asset managers) and equity market volatility (which creates allocation opportunities across sectors). Additionally, the broader asset-management industry benefits from rising inflows into passive and ESG-focused products, a trend that can enhance BCAT’s underlying holdings.

For a deeper quantitative breakdown and scenario analysis, you may find ValueRay’s BCAT profile a useful next step.

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income: 194.4m TTM > 0 and > 6% of Revenue
FCF/TA: 0.19 > 0.02 and ΔFCF/TA 10.32 > 1.0
NWC/Revenue: -96.73% < 20% (prev -73.99%; Δ -22.75% < -1%)
CFO/TA 0.19 > 3% & CFO 354.9m > Net Income 194.4m
Net Debt (-6.30m) to EBITDA (194.4m): -0.03 < 3
Current Ratio: 0.03 > 1.5 & < 3
Outstanding Shares: last quarter (104.8m) vs 12m ago -3.11% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 10.01% > 50% (prev 9.93%; Δ 0.08% > 0%)
Interest Coverage Ratio: 138.5 > 6 (EBITDA TTM 194.4m / Interest Expense TTM 1.40m)

Altman Z'' -0.52

A: -0.10 (Total Current Assets 6.30m - Total Current Liabilities 197.5m) / Total Assets 1.87b
B: -0.04 (Retained Earnings -79.8m / Total Assets 1.87b)
C: 0.10 (EBIT TTM 194.4m / Avg Total Assets 1.97b)
D: -0.36 (Book Value of Equity -79.8m / Total Liabilities 224.0m)
Altman-Z'' Score: -0.52 = B

What is the price of BCAT shares?

As of February 08, 2026, the stock is trading at USD 14.83 with a total of 754,334 shares traded.
Over the past week, the price has changed by +0.88%, over one month by +4.69%, over three months by +7.85% and over the past year by +18.36%.

Is BCAT a buy, sell or hold?

BlackRock Capital has no consensus analysts rating.

What are the forecasts/targets for the BCAT price?

Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 21.4 44.4%

BCAT Fundamental Data Overview February 02, 2026

P/E Trailing = 9.7351
P/S = 9.6969
P/B = 0.9413
Revenue TTM = 197.7m USD
EBIT TTM = 194.4m USD
EBITDA TTM = 194.4m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -6.30m USD (from netDebt column, last fiscal year)
Enterprise Value = 1.54b USD (1.54b + (null Debt) - CCE 3.88m)
Interest Coverage Ratio = 138.5 (Ebit TTM 194.4m / Interest Expense TTM 1.40m)
EV/FCF = 4.33x (Enterprise Value 1.54b / FCF TTM 354.9m)
FCF Yield = 23.10% (FCF TTM 354.9m / Enterprise Value 1.54b)
FCF Margin = 179.5% (FCF TTM 354.9m / Revenue TTM 197.7m)
Net Margin = 98.35% (Net Income TTM 194.4m / Revenue TTM 197.7m)
Gross Margin = unknown ((Revenue TTM 197.7m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 0.82 (Enterprise Value 1.54b / Total Assets 1.87b)
Interest Expense / Debt = unknown (Interest Expense 1.40m / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 153.6m (EBIT 194.4m * (1 - 21.00%))
Current Ratio = 0.03 (Total Current Assets 6.30m / Total Current Liabilities 197.5m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = -0.03 (Net Debt -6.30m / EBITDA 194.4m)
Debt / FCF = -0.02 (Net Debt -6.30m / FCF TTM 354.9m)
Total Stockholder Equity = 1.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.85% (Net Income 194.4m / Total Assets 1.87b)
RoE = 10.94% (Net Income TTM 194.4m / Total Stockholder Equity 1.78b)
RoCE = 11.65% (EBIT 194.4m / Capital Employed (Total Assets 1.87b - Current Liab 197.5m))
RoIC = 11.68% (EBIT 194.4m / (Assets 1.87b - Curr.Liab 197.5m - Cash 3.88m))
WACC = 7.88% (E(1.54b)/V(1.54b) * Re(7.88%) + (debt-free company))
Discount Rate = 7.88% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -1.26%
[DCF Debug] Terminal Value 81.65% ; FCFF base≈285.5m ; Y1≈352.1m ; Y5≈599.7m
Fair Price DCF = 99.19 (EV 10.39b - Net Debt -6.30m = Equity 10.39b / Shares 104.8m; r=7.88% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -46.77 | EPS CAGR: -94.86% | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0

Additional Sources for BCAT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle